Neutrophil to Lymphocyte Ratio in Patients With a First Episode of Psychosis: A Two-Year Longitudinal Follow-up Study.
NLR
antipsychotics
first episode
inflammation
neutrophil to lymphocyte ratio
psychosis
schizophrenia
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
18 11 2022
18 11 2022
Historique:
pubmed:
26
7
2022
medline:
22
11
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
A pro-inflammatory phenotype has been related to psychotic disorders. The neutrophil-lymphocyte ratio (NLR) is an accessible biomarker that could be helpful to characterize this systemic inflammation state. This study evaluated the NLR in a cohort of 310 subjects with a first episode of psychosis (FEP) and a matched group of 215 healthy controls, recruited in 16 Spanish centers participating in the PEPs Project. We investigated the NLR measures over 2 years in a prospective, naturalistic study. At baseline, the FEP group showed a significant higher mean NLR compared to the control group (1.96 ± 1.11 vs 1.72 ± 0.74, P = 0.03). These ratio differences between groups grew at the 24 months follow-up visit (2.04 ± 0.86 vs 1.65 ± 0.65, P < 0.001). Within the FEP group, there were no significant differences in NLR across the follow-up visits, between genders or diagnosis groups (affective vs nonaffective). NLR values did not correlate with the Positive and Negative Symptoms Scale scores. The group of patients who did not reach remission criteria at the end of the study showed a significant higher NLR than those who remitted (2.1896 ± 0.85 vs 1.95 ± 0.87, P = 0.042). A significant correlation between antipsychotic doses and NLR was found at the two-years follow-up visit (r=0.461, P < 0.001). Our results highlight the existence of an underlying predisposition of FEP patients to present an increased mean NLR. The use of NLR in clinical practice could be helpful to identify this inflammatory imbalance.
Sections du résumé
BACKGROUND AND HYPOTHESIS
A pro-inflammatory phenotype has been related to psychotic disorders. The neutrophil-lymphocyte ratio (NLR) is an accessible biomarker that could be helpful to characterize this systemic inflammation state.
STUDY DESIGN
This study evaluated the NLR in a cohort of 310 subjects with a first episode of psychosis (FEP) and a matched group of 215 healthy controls, recruited in 16 Spanish centers participating in the PEPs Project. We investigated the NLR measures over 2 years in a prospective, naturalistic study.
STUDY RESULTS
At baseline, the FEP group showed a significant higher mean NLR compared to the control group (1.96 ± 1.11 vs 1.72 ± 0.74, P = 0.03). These ratio differences between groups grew at the 24 months follow-up visit (2.04 ± 0.86 vs 1.65 ± 0.65, P < 0.001). Within the FEP group, there were no significant differences in NLR across the follow-up visits, between genders or diagnosis groups (affective vs nonaffective). NLR values did not correlate with the Positive and Negative Symptoms Scale scores. The group of patients who did not reach remission criteria at the end of the study showed a significant higher NLR than those who remitted (2.1896 ± 0.85 vs 1.95 ± 0.87, P = 0.042). A significant correlation between antipsychotic doses and NLR was found at the two-years follow-up visit (r=0.461, P < 0.001).
CONCLUSIONS
Our results highlight the existence of an underlying predisposition of FEP patients to present an increased mean NLR. The use of NLR in clinical practice could be helpful to identify this inflammatory imbalance.
Identifiants
pubmed: 35876785
pii: 6649676
doi: 10.1093/schbul/sbac089
pmc: PMC9673249
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1327-1335Investigateurs
Santiago Madero
(S)
Jairo González
(J)
Álvaro Andreu-Bernabeu
(Á)
Sandra Recio
(S)
Judit Selma
(J)
Maria Tonda
(M)
Edurne García-Corres
(E)
Jéssica Fernández-Sevillano
(J)
Concepción De-la-Cámara
(C)
Pedro Modrego-Pardo
(P)
Mª José Escartí
(MJ)
Marta Pérez-Rando
(M)
Guillermo Vázquez
(G)
Silvia Cristeto
(S)
Jose Sanchez-Moreno
(J)
Anna Gimenez-Palomo
(A)
Josefina Castro-Fornieles
(J)
Elena de la Serna
(E)
Fernando Contreras
(F)
Leticia González-Blanco
(L)
Pilar A Sáiz
(P)
Miguel Gutiérrez-Fraile
(M)
Arantzazu Zabala
(A)
Luis Sanchez-Pastor
(L)
Roberto Rodriguez-Jimenez
(R)
Judith Usall
(J)
Anna Butjosa
(A)
Edith Pomarol-Clotet
(E)
Salvador Sarró
(S)
Ángela Ibáñez
(Á)
Ana M Sánchez-Torres
(AM)
Vicent Balanzá
(V)
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Cancer. 2018 Feb 12;9(5):861-871
pubmed: 29581764
Int J Neuropsychopharmacol. 2014 Oct 31;18(2):
pubmed: 25577666
Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):397-403
pubmed: 26792137
Schizophr Bull. 2022 Jan 21;48(1):47-55
pubmed: 34480476
Front Psychiatry. 2021 Sep 16;12:728990
pubmed: 34603107
J Am Acad Child Adolesc Psychiatry. 2005 Oct;44(10):1024-31
pubmed: 16175107
Schizophr Bull. 2019 Jun 18;45(4):742-751
pubmed: 30169868
Australas Psychiatry. 2020 Aug;28(4):454-458
pubmed: 32174125
Mol Psychiatry. 2019 Jun;24(6):869-887
pubmed: 30116031
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):229-236
pubmed: 29535038
Neurosci Biobehav Rev. 2015 Aug;55:612-26
pubmed: 26092265
Schizophr Bull. 2019 Jun 18;45(4):846-858
pubmed: 30107610
Acta Psychiatr Scand. 2020 Jul;142(1):18-26
pubmed: 31850530
Int J Neuropsychopharmacol. 2016 Mar 31;19(4):
pubmed: 26506856
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
Gen Hosp Psychiatry. 2019 Nov - Dec;61:86-87
pubmed: 31280919
J Psychiatr Res. 2021 Nov;143:38-42
pubmed: 34438202
Schizophr Bull. 2014 Mar;40(2):376-87
pubmed: 23486748
Lancet. 2022 Jan 29;399(10323):473-486
pubmed: 35093231
Vojnosanit Pregl. 2015 Dec;72(12):1085-92
pubmed: 26898032
Schizophr Bull. 2020 Feb 26;46(2):363-373
pubmed: 31504969
J Clin Med. 2021 Apr 29;10(9):
pubmed: 33946871
Schizophr Res. 2018 Mar;193:188-196
pubmed: 28663026
Schizophr Bull. 2016 Jan;42(1):142-51
pubmed: 26130821
Eur Neuropsychopharmacol. 2021 Oct;51:132-133
pubmed: 34284277
Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994 Jul-Aug;22(4):171-7
pubmed: 7810373
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Rev Psiquiatr Salud Ment (Engl Ed). 2019 Jul - Sep;12(3):135-140
pubmed: 31103407
Psychiatry Res. 2019 Jan;271:131-135
pubmed: 30472508
Psychiatry Res. 2018 Feb;260:307-312
pubmed: 29223800
Br J Cancer. 2019 May;120(11):1045-1051
pubmed: 31015558
Am J Psychiatry. 2005 Mar;162(3):441-9
pubmed: 15741458
Rev Psiquiatr Salud Ment. 2013 Jan-Mar;6(1):4-16
pubmed: 23206389
World J Biol Psychiatry. 2020 Jun;21(5):326-338
pubmed: 30806142
Psychiatr Danub. 2014 Sep;26(3):220-5
pubmed: 25191768
Biol Psychiatry. 2022 Oct 1;92(7):563-572
pubmed: 35659385
Harv Rev Psychiatry. 2022 Jan-Feb 01;30(1):59-70
pubmed: 34995036
Psychiatry Res. 2022 Feb;308:114382
pubmed: 34995832
Rev Psiquiatr Salud Ment (Engl Ed). 2019 Jan - Mar;12(1):1-8
pubmed: 30416047
Arch Gen Psychiatry. 2007 Jan;64(1):19-28
pubmed: 17199051
Schizophr Res. 2019 Apr;206:4-12
pubmed: 30573407
Schizophr Bull. 2020 Jul 8;46(4):1019-1025
pubmed: 32083289
Early Interv Psychiatry. 2019 Feb;13(1):95-100
pubmed: 28786532